ストックスクリーナーアプリを入手
2.82
1.81%
0.05
前日終値:
$2.77
開ける：
$2.8
24時間の取引高:
65,670
Relative Volume:
0.07
時価総額：
$22.54M
収益：
-
当期純損益:
$-20.84M
株価収益率:
-0.3824
EPS:
-7.3739
ネットキャッシュフロー:
$-18.59M
1週間 パフォーマンス:
+0.36%
1か月 パフォーマンス:
+24.78%
6か月 パフォーマンス:
-8.44%
1年 パフォーマンス:
-42.80%
1日の値動き範囲:
$2.7101
$2.87
1週間の範囲:
$2.60
$2.87
52週間の値動き範囲:
$2.20
$6.52
Cellectar Biosciences Inc Stock (CLRB) Company Profile
名前
Cellectar Biosciences Inc
セクター
電話
(608) 441-8120
住所
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
2.82 | 22.54M | 0 | -20.84M | -18.59M | -7.3739 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | アップグレード | Maxim Group | Hold → Buy |
| 2024-12-05 | 再開されました | Ladenburg Thalmann | Buy |
| 2020-07-01 | 開始されました | Oppenheimer | Outperform |
| 2020-01-21 | 再開されました | ROTH Capital | Buy |
| 2019-09-13 | 開始されました | ROTH Capital | Buy |
| 2016-12-21 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk - Yahoo Finance
Form 4 Cellectar Biosciences Inc For: 10 July - Investing.com India
Cellectar Biosciences, Inc. Files Form 8-K: Updated Stock Incentive Plan and Corporate Details for 2026 - Minichart
Form 4 Cellectar Biosciences Inc For: 10 July By Investing.com - Investing.com Nigeria
Cellectar Biosciences (NASDAQ: CLRB) awards 15,000 stock options to consultant - Stock Titan
Cellectar Biosciences (NASDAQ: CLRB) holders approve more stock awards and large warrant exercise - Stock Titan
Form 4 Cellectar Biosciences Inc For: 8 July By Investing.com - Investing.com Nigeria
Cellectar Biosciences (CLRB) CEO awarded 250,000 stock options - Stock Titan
Cellectar Biosciences (CLRB) grants COO 118,000 stock options - Stock Titan
Consultant for Cellectar (NASDAQ: CLRB) receives grant of 15,000 stock options - Stock Titan
CLRBCellectar Biosciences Inc Options - Finviz
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
Price to book forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Enterprise value to EBIT forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Price to earnings forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Enterprise value to EBITDA forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
Cellectar Biosciences, Inc. Actuals & Estimates (NASDAQ:CLRB) - TradingView
Enterprise value to revenue forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB - TradingView
CLRB Forecast — Price Target — Prediction for 2027 - TradingView
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Cellectar Biosciences Inc (CLRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cellectar Biosciences Inc (CLRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cellectar Biosciences Inc (CLRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cellectar Biosciences Inc (CLRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cellectar Biosciences Inc (CLRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cellectar Biosciences Inc (CLRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cellectar Biosciences Inc (CLRB) Institutional Confidence - TradingKey
Cellectar Biosciences (CLRB) Edges Higher: Consolidation Near Key ResistanceFund Manager Survey - newsline.com
Cellectar Biosciences Inc (CLRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cellectar Biosciences Inc (CLRB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cellectar Biosciences (CLRB) Slides 4.27% as Support Test LoomsInstitutional Flow Picks - dars.gov.et
Number of shareholders of Cellectar Biosciences, Inc. – MUN:NV40 - TradingView
Cellectar Biosciences (CLRB) director Andrew Gu submits initial Form 3 ownership filing - Stock Titan
Cellectar Biosciences (CLRB) Declines 3.09% as Stock Tests Support Near $2.38Swing Entry Signals - newsline.com
Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB) - Stock Titan
Cellectar Biosciences (CLRB) Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress ContinuesProfit Announcement - newsline.com
[EFFECT] Cellectar Biosciences, Inc. SEC Filing - Stock Titan
Cellectar Biosciences (CLRB) registers 51.998M shares for resale; board seat named - Stock Titan
Cellectar plans phase 3 trial for WM treatment after BTKi - Investing.com UK
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting - Investing News Network
Cellectar plans phase 3 trial for WM treatment after BTKi By Investing.com - Investing.com South Africa
Cellectar Biosciences to Highlight Compelling New Efficacy - GlobeNewswire
Cellectar Biosciences Q1 2026 earnings preview - MSN
Cellectar (NASDAQ: CLRB) details 51.9M-share resale tied to May 2026 financing - Stock Titan
CLRB Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineManagement Guidance Update - dars.gov.et
Cellectar Biosciences (CLRB) upgraded to buy: Here's what you should know - MSN
Large warrant exercise and equity plan votes ahead for Cellectar (NASDAQ: CLRB) - Stock Titan
Cellectar Biosciences (CLRB) Edges Higher: Support Levels Tested as Biotech Sector Shows Mixed SignalsFundamental Weighted - newsline.com
Cellectar Biosciences Edges Higher, Finding Support Near $3.04Growth Stock Picks - The Legal Advocate
Cellectar Biosciences Bets on Iopofosine Breakthrough - TipRanks
Cellectar Biosciences Files for Secondary Offering of Common Shares - Moomoo
Cellectar Biosciences Inc (CLRB) 財務データ
収益
当期純利益
現金流量
EPS
Cellectar Biosciences Inc (CLRB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| CARUSO JAMES V | Chief Executive Officer |
May 07 '26 |
Buy |
2.88 |
8,680 |
24,998 |
20,318 |
| NEIS JOHN | Director |
Dec 12 '25 |
Sale |
3.70 |
198 |
732 |
10 |
2.64%
大文字化:
|
ボリューム (24 時間):